A precise and non-toxic treatment that targets lung cancer cells at the nanoscale is able to effectively kill the cells even at a low dose.
Researchers from Washington State University and the Department of Energy’s Pacific Northwest National Laboratory (PNNL) used tiny tubes made from organic molecules called peptoids to deliver cancer-killing drugs in a targeted manner. The research, led by Yuehe Lin, professor in WSU’s School of Mechanical and Materials Engineering, and Chun-Long Chen, a senior research scientist at PNNL and a joint faculty fellow at the University of Washington, was published as the cover story in the prestigious journal Small.
The biologically-inspired nanotubes, which are about a hundred thousand times thinner than a human hair, were rolled up from membrane-like nanosheets. The drug molecules, fluorescent dyes and cancer-targeting molecules were precisely placed within the nanotubes, enabling them to track the efficiency of drug delivery into the cancer cells.
The new technology allows the two drugs – one for chemotherapy and the other for a less-invasive photodynamic therapy treatment – to be delivered directly to the cancer cells. Photodynamic therapy uses a chemical that, when exposed to light, releases reactive oxygen species (ROS) that kill cancer cells. The researchers’ dual-drug approach enabled the use of a lower dose of the cancer drugs than using a single drug, leading to effective killing of cancer cells with low toxicity.
“By precisely engineering these nanotubes with fluorescent dyes and cancer targeting molecules, scientists can clearly locate tumor cells and track how the drug regimen is performing,” said Lin. “We can also track how nanotubes enter and deliver the drugs inside the cancer cell.”
The team tested the nanotubes on lung cancer cells and found that they delivered the chemotherapy drug doxorubicin directly into the fast-dividing cancer cells, resulting in highly efficient cancer killing while using less chemotherapy drugs.
“This is a promising approach for precision targeting with little damage to healthy surrounding cells,” said Lin.
While other nanomaterials, such as carbon nanotubes, have been used to deliver and track cancer-killing drugs, researchers have found that they are toxic to the body. Furthermore, they didn’t do well at precisely recognizing molecules.
“By using these peptoids, we were able to develop highly programmable nanotubes and a biocompatible delivery mechanism,” said Chen. “We also harnessed the high stability of peptoid and its well-controlled packing to develop nanotubes that are highly stable.”
“Due to their unique structure, these nanotubes can be easily assembled for use in cancer therapy and stay in the body longer for treatment,” said Lin.
The team is now looking for collaboration and funding opportunities with pharmaceutical companies to extend the research into animal and clinical studies.
The Latest on: Lung cancer
via Google News
The Latest on: Lung cancer
- Hall of Famer Lafleur has recurrence of lung canceron October 7, 2020 at 10:53 am
Legeldary Montreal Canadiens forward Guy Lafleur has experienced a recurrence of lung cancer, the Centre Hospitalier de l’Universite de Montreal (CHUM) announced on Wednesday. Lafleur, 69, had surgery ...
- Guy Lafleur Facing a Relapse of his Lung Canceron October 7, 2020 at 10:51 am
The Centre hospitalier de l'Université de Montréal (CHUM) must regrettably announce that Mr. Guy Lafleur is facing a relapse of his lung cancer. This news was disclosed to him during a follow-up ...
- Montreal Canadiens great Guy Lafleur resumes treatment as lung cancer returnson October 7, 2020 at 10:31 am
Montreal Canadiens great Guy Lafleur is facing a recurrence of lung cancer, the hospital treating him announced Wednesday.
- Bristol Myers' Opdivo shows incremental benefit over chemo in lung cancer studyon October 7, 2020 at 5:20 am
Bristol (NYSE:BMY) announces the successful outcome of a Phase 3 clinical trial, CheckMate-816, evaluating the combination of Opdivo (nivolumab) and chemo administered before surgery in patients with ...
- Bristol-Myers Shares Gain After Positive Data From Opdivo Lung Cancer Trialon October 7, 2020 at 4:42 am
Myers said its blockbuster drug, Opdivo, as well as chemotherapy helped patients suffering from resectable non-small cell lung cancer in a late-stage trial.
- Bristol Myers' Opdivo succeeds in late-stage lung cancer trialon October 7, 2020 at 4:36 am
In the trial, significantly more non-small cell lung cancer patients treated with Opdivo and chemotherapy before surgery showed no evidence of cancer cells in their resected tissue compared with those ...
- 7 Signs You Have Lung Cancer, Like the Late Eddie Van Halenon October 7, 2020 at 4:20 am
On Tuesday the world lost a rock legend when Eddie Van Halen died at the age of 65 after a "long and arduous battle with cancer," according to his son. His ex-wife Valerie Bertinelli reports that the ...
- 10 Ways to Reduce Your Lung Cancer Risk, in Light of Eddie Van Halenon October 7, 2020 at 4:11 am
According to Matthew Mintz, MD, even if you aren't a chain smoker you should consider kicking the habit for good. "While there is certainly a dose relationship between smoking and lung disease, no ...
- Amgen announces ‘positive’ Phase II lung cancer results for cancer drug with hard-to-reach targeton October 6, 2020 at 7:26 pm
The company did not provide data, but said results for patients who received sotorasib at the 960mg dose were consistent with those seen in the Phase I portion of the Phase I/II study, which showed an ...
- Team to Run/Walk 1000 Miles to Raise $1k for Lung Cancer Researchon October 6, 2020 at 12:08 pm
One of your neighbors posted in Health & Fitness. Click through to read what they have to say. (The views expressed in this post are the author’s own.) ...
via Bing News